

Starch Indicator, 0.5% (W/V) ALPHA CHEMICALS PTY LTD

Chemwatch Hazard Alert Code: 2

Issue Date: **05/07/2024** Print Date: **14/11/2024** S.GHS.AUS.EN

Chemwatch: 10-35711 Version No: 2.1

Safety Data Sheet according to Work Health and Safety Regulations (Hazardous Chemicals) 2023 and ADG requirements

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier Product name Starch Indicator, 0.5% (W/V) Chemical Name Not Applicable Synonyms Not Available Chemical formula Not Applicable Other means of identification Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	General Laboratory Reagent Use according to manufacturer's directions.
	Use according to manufacturer's directions.

Details of the manufacturer or supplier of the safety data sheet

Registered company name	ALPHA CHEMICALS PTY LTD	
Address	4 ALLEN PLACE WETHERILL PARK NSW 2164 Australia	
Telephone	61 (0)2 9982 4622	
Fax	Not Available	
Website	~	
Email	shane@alphachem.com.au	

Emergency telephone number

Association / Organisation	ALPHA CHEMICALS PTY LTD	CHEMWATCH EMERGENCY RESPONSE (24/7)
Emergency telephone number(s)	61 (0)418 237 771	+61 1800 951 288
Other emergency telephone number(s)	Not Available	+61 3 9573 3188

Once connected and if the message is not in your preferred language then please dial 01

SECTION 2 Hazards identification

Classification of the substance or mixture

NON-HAZARDOUS CHEMICAL. NON-DANGEROUS GOODS. According to the WHS Regulations and the ADG Code.

Chemwatch Hazard Ratings

Min Max	
)	
1	0 = Minimum
2	1 = Low
)	2 = Moderate
)	3 = High 4 = Extreme
)

Poisons Schedule	Not Applicable	
Classification [1]	Non hazardous	
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI	

Label elements

Hazard pictogram(s)	Not Applicable	
Signal word	Not Applicable	

Hazard statement(s)

Not Applicable

Chemwatch: 10-35711 Page 2 of 10 Issue Date: 05/07/2024
Version No: 2.1 Print Date: 14/11/2024

Starch Indicator, 0.5% (W/V)

Precautionary statement(s) Prevention

Not Applicable

Precautionary statement(s) Response

Not Applicable

Precautionary statement(s) Storage

Not Applicable

Precautionary statement(s) Disposal

Not Applicable

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
9005-84-9	0.49	starch, soluble
69-72-7	0.12	salicylic acid
7732-18-5	99.37	Distilled Water
Legend:	Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L * EU IOELVs available	

SECTION 4 First aid measures

Description of first aid measures

upper and lower lids. Seek medical attention without delay; if pain persists or recurs		 Wash out immediately with fresh running water. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the
Skin Contact If skin contact occurs: Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available). Seek medical attention in event of irritation.		 Immediately remove all contaminated clothing, including footwear. Flush skin and hair with running water (and soap if available).
 Inhalation If fumes, aerosols or combustion products are inhaled remove from contaminated area. Other measures are usually unnecessary. 		· · · · · · · · · · · · · · · · · · ·
	Ingestion	 If swallowed do NOT induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. Observe the patient carefully. Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. Seek medical advice.

Indication of any immediate medical attention and special treatment needed

for salicylate intoxication:

- · Pending gastric lavage, use emetics such as syrup of Ipecac or delay gastric emptying and absorption by swallowing a slurry of activated charcoal. Do not give ipecac after charcoal.
- · Gastric lavage with water or perhaps sodium bicarbonate solution (3%-5%). Mild alkali delays salicylate absorption from the stomach and perhaps slightly from the duodenum.
- · Saline catharsis with sodium or magnesium sulfate (15-30 gm in water).
- · Take an immediate blood sample for an appraisal of the patient's acid-base status. A pH determination on an anaerobic sample of arterial blood is best. An analysis of the plasma salicylate concentration should be made at the same time. Laboratory controls are almost essential for the proper management of severe salicylism.
- · In the presence of an established acidosis, alkali therapy is essential, but at least in an adult, alkali should be withheld until its need is demonstrated by chemical analysis. The intensity of treatment depends on the intensity of acidosis. In the presence of vomiting, intravenous sodium bicarbonate is the most satisfactory of all alkali therapy.
- · Correct dehydration and hypoglycaemia (if present) by the intravenous administration of glucose in water or in isotonic saline. The administration of glucose may also serve to remedy ketosis which is often seen in poisoned children.
- · Even in patients without hypoglycaemia, infusions of glucose adequate to produce distinct hyperglycaemia are recommended to prevent glucose depletion in the brain. This recommendation is based on impressive experimental data in animals.
- Renal function should be supported by correcting dehydration and incipient shock. Overhydration is not justified. An alkaline urine should be maintained by the administration of alkali if necessary with care to prevent a severe systemic alkalosis. As long as urine remains alkaline (pH above 7.5), administration of an osmotic diuretic such as mannitol or perhaps THAM is useful, but one must be careful to avoid hypokalaemia. Supplements of potassium chloride should be included in parenteral fluids.
- · Small doses of barbiturates, diazepam, paraldehyde, or perhaps other sedatives (but probably not morphine) may be required to suppress extreme restlessness and convulsions.
- · For hyperpyrexia, use sponge baths.
- The presence of petechiae or other signs of haemorrhagic tendency calls for a large Vitamin K dose and perhaps ascorbic acid. Minor transfusions may be necessary since bleeding in salicylism is not always due to a prothrombin effect.
- · Haemodialysis and haemoperfusion have proved useful in salicylate poisoning, as have peritoneal dialysis and exchange transfusions, but alkaline diuretic therapy is probably sufficient except in fulminating cases.

[GOSSELIN, et.al.: Clinical Toxicology of Commercial Products]

The mechanism of the toxic effect involves metabolic acidosis, respiratory alkalosis, hypoglycaemia, and potassium depletion. Salicylate poisoning is characterised by extreme acid-base disturbances, electrolyte disturbances and decreased levels of consciousness. There are differences between acute and chronic toxicity and a varying clinical picture which is dependent on the age of the patient and their kidney function. The major feature of poisoning is metabolic acidosis due to "uncoupling of oxidative phosphorylation" which produces an increased metabolic rate, increased oxygen consumption, increased formation of carbon dioxide, increased heat production and increased utilisation of glucose. Direct stimulation of the respiratory centre leads to hyperventilation and respiratory alkalosis. This leads to compensatory increased renal excretion of bicarbonate which contributes to the metabolic acidosis which may coexist or develop subsequently. Hypoglycaemia may occur as a result of increased glucose demand, increased rates of tissue glucosylvis, and impaired rate of glucose synthesis. NOTE: Tissue glucose levels may be lower than plasma levels. Hyperglycaemia may occur due to increased glycogenolysis. Potassium depletion occurs as a result of increased renal excretion as well as intracellular movement of potassium.

Salicylates competitively inhibit vitamin K dependent synthesis of factors II, VII, IX, X and in addition, may produce a mild dose dependent hepatitis. Salicylates are bound to albumin. The extent of protein binding is concentration dependent (and falls with higher blood levels). This, and the effects of acidosis, decreasing ionisation, means that the volume of distribution increases markedly in overdose as does CNS penetration. The extent of protein binding (50-80%) and the rate of metabolism are concentration dependent.

Chemwatch: 10-35711 Page 3 of 10

Starch Indicator, 0.5% (W/V)

Issue Date: 05/07/2024 Version No: 2.1 Print Date: 14/11/2024

Hepatic clearance has zero order kinetics and thus the therapeutic half-life of 2-4.5 hours but the half-life in overdose is 18-36 hours. Renal excretion is the most important route in overdose. Thus when the salicylate concentrations are in the toxic range there is increased tissue distribution and impaired clearance of the drug.

HyperTox 3.0 https://www.ozemail.com.au/-ouad/SALI0001.HTA

Treat symptomatically

for non-steroidal anti-inflammatories (NSAIDs)

- Symptoms following acute NSAIDs overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression, and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose
- ▶ Patients should be managed by symptomatic and supportive care following a NSAIDs overdose.
- There are no specific antidotes.
- Emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 g/kg in children), and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose (5 to 10 times the usual dose).
- Forced diuresis, alkalinisation of urine, hemodialysis, or haemoperfusion may not be useful due to high protein binding.
- For gastrointestinal haemorrhage, monitor stool guaiac and administer antacids or sucralfate.
- For mild/moderate allergic reactions, administer antihistamines with or without inhaled beta agonists, corticosteroids, or epinephrine
- For severe allergic reactions, administer oxygen, antihistamines, epinephrine, or corticosteroids. Nephritis or nephrotic syndrome, thrombocytopenia, or haemolytic anemia may respond to glucocorticoid administration.
- For severe acidosis, administer sodium bicarbonate.
- Administer as required: plasma volume expanders for severe hypotension; diazepam or other benzodiazepine for convulsions; vitamin K1 for hypoprothrombinaemia; and/or dopamine plus dobutamine intravenously to prevent or reverse early indications of renal failure.

Serious gastrointestinal toxicity, such as bleeding, ulceration, and perforation, can occur at any time, with or without warning symptoms, in patients treated chronically with NSAID therapy. Although minor upper gastrointestinal problems, such as dyspepsia, are common, usually developing early in therapy, physicians should remain alert for ulceration and bleeding in patients treated chronically with NSAIDs even in the absence of previous GI tract symptoms. In patients observed in clinical trials of several months to two years duration, symptomatic upper GI ulcers, gross bleeding or perforation appear to occur in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. Physicians should inform patients about the signs and/or symptoms of serious GI toxicity and what steps to take if they occur. Studies to date have not identified any subset of patients not at risk of developing peptic ulceration and bleeding. Except for a prior history of serious GI events and other risk factors known to be associated with peptic ulcer disease, such as alcoholism, smoking, etc., no risk factors (e.g., age, sex) have been associated with increased risk. Elderly or debilitated patients seem to tolerate ulceration or bleeding less well than other individuals, and most spontaneous reports of fatal GI events are in this population. Studies to date are inconclusive concerning the relative risk of various NSAIDs in causing such reactions. High doses of any NSAID probably carry a greater risk of these reactions, although controlled clinical trials showing this do not exist in most cases. In considering the use of relatively large doses (within the recommended dosage range), sufficient benefit should be anticipated to offset the potential increased risk of GI toxicity.

SECTION 5 Firefighting measures

Extinguishing media

The product contains a substantial proportion of water, therefore there are no restrictions on the type of extinguishing media which may be used. Choice of extinguishing media should take into account surrounding areas.

Though the material is non-combustible, evaporation of water from the mixture, caused by the heat of nearby fire, may produce floating layers of combustible substances. In such an event consider:

- foam.
- dry chemical powder.
- carbon dioxide.

Special hazards arising from the substrate or mixture

Special nazarus arising from the substrate of mixture			
Fire Incompatibility	None known.		
Advice for firefighters			
Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves in the event of a fire. Prevent, by any means available, spillage from entering drains or water courses. Use fire fighting procedures suitable for surrounding area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use. 		
Fire/Explosion Hazard	 The material is not readily combustible under normal conditions. However, it will break down under fire conditions and the organic component may burn. Not considered to be a significant fire risk. Heat may cause expansion or decomposition with violent rupture of containers. Decomposes on heating and may produce toxic fumes of carbon monoxide (CO). May emit acrid smoke. Decomposes on heating and produces toxic fumes of: carbon dioxide (CO2) other pyrolysis products typical of burning organic material. May emit poisonous fumes. 		
HAZCHEM	Not Applicable		

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up		
Minor Spills	 Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. Control personal contact with the substance, by using protective equipment. Contain and absorb spill with sand, earth, inert material or vermiculite. Wipe up. Place in a suitable, labelled container for waste disposal. 	
Major Spills	Moderate hazard. ▶ Clear area of personnel and move upwind.	

Page 4 of 10

Chemwatch: 10-35711 Issue Date: 05/07/2024 Version No: 2.1 Print Date: 14/11/2024 Starch Indicator, 0.5% (W/V)

- Alert Fire Brigade and tell them location and nature of hazard.
- Wear breathing apparatus plus protective gloves.
- Prevent, by any means available, spillage from entering drains or water course.
- Stop leak if safe to do so.
- ▶ Contain spill with sand, earth or vermiculite.
- Collect recoverable product into labelled containers for recycling.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

- Avoid all personal contact, including inhalation.
 - Wear protective clothing when risk of exposure occurs.
 - ▶ Use in a well-ventilated area.
 - Prevent concentration in hollows and sumps.
 - ▶ DO NOT enter confined spaces until atmosphere has been checked.
 - DO NOT allow material to contact humans, exposed food or food utensils
 - Avoid contact with incompatible materials.
 - When handling, DO NOT eat, drink or smoke

Other information

Safe handling

- Store in original containers.
- Keep containers securely sealed.
- Store in a cool, dry, well-ventilated area.
- Store away from incompatible materials and foodstuff containers
- Protect containers against physical damage and check regularly for leaks.
- Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

Suitable container

- Glass container is suitable for laboratory quantities
- Polyethylene or polypropylene container
- Packing as recommended by manufacturer
- Check all containers are clearly labelled and free from leaks.

Storage incompatibility

None known

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Not Available

Trot/ trailable		
Ingredient	Original IDLH	Revised IDLH
starch, soluble	Not Available	Not Available
salicylic acid	Not Available	Not Available
Distilled Water	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
salicylic acid	E ≤ 0.01 mg/m³	
Notes:	Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.	

Exposure controls

Appropriate engineering controls

Enclosed local exhaust ventilation is required at points of dust, fume or vapour generation.

HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapours.

Barrier protection or laminar flow cabinets should be considered for laboratory scale handling.

A fume hood or vented balance enclosure is recommended for weighing/ transferring quantities exceeding 500 mg.

When handling quantities up to 500 gram in either a standard laboratory with general dilution ventilation (e.g. 6-12 air changes per hour) is preferred. Quantities up to 1 kilogram may require a designated laboratory using fume hood, biological safety cabinet, or approved vented enclosures. Quantities exceeding 1 kilogram should be handled in a designated laboratory or containment laboratory using appropriate barrier/ containment technology.

Manufacturing and pilot plant operations require barrier/ containment and direct coupling technologies.

Individual protection measures, such as personal protective equipment









When handling very small quantities of the material eye protection may not be required.

For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs: Chemical goggles, [AS/NZS 1337.1, EN166 or national equivalent]

Eve and face protection

Face shield. Full face shield may be required for supplementary but never for primary protection of eyes.

Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available.

Skin protection

See Hand protection below

Hands/feet protection

The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

Starch Indicator, 0.5% (W/V)

Print Date: 14/11/2024

Issue Date: 05/07/2024

The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice. Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended. Suitability and durability of glove type is dependent on usage. Rubber gloves (nitrile or low-protein, powder-free latex, latex/ nitrile). Employees allergic to latex gloves should use nitrile gloves in preference Double gloving should be considered. PVC gloves ▶ Change gloves frequently and when contaminated, punctured or torn. Wash hands immediately after removing gloves. Protective shoe covers. [AS/NZS 2210] Head covering. **Body protection** See Other protection below ▶ For quantities up to 500 grams a laboratory coat may be suitable. For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers. Other protection For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection. Ensure there is ready access to an emergency shower.

Recommended material(s)

Version No. 2.1

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the computergenerated selection:

▶ For Emergencies: Vinyl suit

Starch Indicator, 0.5% (W/V)

Material	СРІ
BUTYL	Α
NEOPRENE	Α
VITON	Α
NATURAL RUBBER	С
PVA	С

- * CPI Chemwatch Performance Index
- A: Best Selection
- B: Satisfactory; may degrade after 4 hours continuous immersion
- C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which $\label{eq:might} \mbox{might otherwise be unsuitable following long-term or frequent use.} \ \mbox{A qualified}$ practitioner should be consulted.

Ansell Glove Selection

Glove — In order of recommendation
TouchNTuff® 92-500
TouchNTuff® 92-600
TouchNTuff® 92-605
TouchNTuff® 93-250
TouchNTuff® 93-700
AlphaTec 02-100
AlphaTec® Solvex® 37-185
AlphaTec® 58-008
AlphaTec® 58-530B
AlphaTec® 58-530W

The suggested gloves for use should be confirmed with the glove supplier.

Respiratory protection

Type A Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Selection of the Class and Type of respirator will depend upon the level of breathing zone contaminant and the chemical nature of the contaminant. Protection Factors (defined as the ratio of contaminant outside and inside the mask) may also be important.

Required minimum protection factor	Maximum gas/vapour concentration present in air p.p.m. (by volume)	Half-face Respirator	Full-Face Respirator
up to 10	1000	A-AUS / Class1	-
up to 50	1000	-	A-AUS / Class 1
up to 50	5000	Airline *	-
up to 100	5000	-	A-2
up to 100	10000	-	A-3
100+			Airline**

- * Continuous Flow ** Continuous-flow or positive pressure demand A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)
 - Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
 - ▶ The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.

 • Cartridge performance is affected by humidity. Cartridges should be changed after
- 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	White translucent liquid; mixes with water.		
Physical state	Liquid	Relative density (Water = 1)	1.0
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Available	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	0	Viscosity (cSt)	Not Available

Chemwatch: **10-35711**Version No: **2.1**

Starch Indicator, 0.5% (W/V)

Issue Date: **05/07/2024**Print Date: **14/11/2024**

Initial boiling point and boiling range (°C)	100	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Available	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Available	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (1%)	5-7
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available
Heat of Combustion (kJ/g)	Not Available	Ignition Distance (cm)	Not Available
Flame Height (cm)	Not Available	Flame Duration (s)	Not Available
Enclosed Space Ignition Time Equivalent (s/m3)	Not Available	Enclosed Space Ignition Deflagration Density (g/m3)	Not Available

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	Unstable in the presence of incompatible materials. Product is considered stable. Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information	οn	toxicolor	nical offects
IIIIOIIIIalioii	UII	LUXICUIUL	aicai eilecis

Inhaled	The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting. Not normally a hazard due to non-volatile nature of product			
Ingestion	Accidental ingestion of the material may be damaging to the health of the individual. High oral doses of salicylates, such as aspirin, may cause a mild burning pain in the throat and stomach, causing vomiting. This is followed (within hours) by deep, rapid breathing, tiredness, nausea and further vomiting, thirst and diarrhoea.			
Skin Contact	The material is not thought to be a skin irritant (as classified by EC Directives using animal models). Temporary discomfort, however, may result from prolonged dermal exposures. Skin contact with the material may damage the health of the individual; systemic effects may result following absorption. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.			
Eye		Although the liquid is not thought to be an irritant (as classified by EC Directives), direct contact with the eye may produce transient discomfort characterised by tearing or conjunctival redness (as with windburn).		
Chronic	Substance accumulation, in the human body, may occur and may cause some concern following repeated or long-term occupational exposure. Chronic exposure to salicylates produce problems with metabolism, central nervous system disturbances, or kidney damage. Those with pre-existing damage to the eye, skin or kidney are especially at risk.			
	TOXICITY	IRRITATION		
Starch Indicator, 0.5% (W/V)	Not Available	Not Available		
	тохісіту	IRRITATION		
starch, soluble	Not Available	Not Available		
	тохісіту	IRRITATION		
	dermal (rat) LD50: >2000 mg/kg ^[2]	Eye (Rodent - rabbit): 100mg		
salicylic acid	Inhalation (Rat) LC50: >0.225 mg/l4h ^[2]	Eye: adverse effect observed (irritating) ^[1]		
	Oral (Cat) LD50; 400 mg/kg ^[2]	Skin: no adverse effect observed (not irritating) ^[1]		
	тохісіту	IRRITATION		
Distilled Water	Oral (Rat) LD50: >90000 mg/kg ^[2]	Not Available		
Legend:	Value obtained from Europe ECHA Registered Substance specified data extracted from RTECS - Register of Toxic Efficiency.	es - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise ect of chemical Substances		

SALICYLIC ACID

Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating

Chemwatch: **10-35711**Version No: **2.1**

Starch Indicator, 0.5% (W/V)

Issue Date: **05/07/2024**Print Date: **14/11/2024**

compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.

The members of this group are rapidly absorbed through the gastrointestinal tract, metabolised primarily in the liver, and excreted primarily in the urine either unchanged or as conjugates of benzoic acid derivatives. At high dose levels, gut micro-organisms may act to produce minor amounts of breakdown products. However, no adverse effects have been reported even at repeated high doses. Similarly, no effects were observed on reproduction, foetal development and tumour potential.

A member or analogue of a group of hydroxy and alkoxy-substituted benzyl derivatives generally regarded as safe (GRAS) based in part on their self-limiting properties as flavouring substances in food; their rapid absorption. metabolic detoxification, and excretion in humans and other animals, their low level of flavour use, the wide margin of safety between the conservative estimates of intake and the no-observed-adverse effect levels determined from chronic and subchronic studies and the lack of significant genotoxic and mutagenic potential. This evidence of safety is supported by the fact that the intake of benzyl derivatives as natural components of traditional foods is greater than the intake as intentionally added flavouring substances.

All members of this group are aromatic primary alcohols, aldehydes, carboxylic acids or their corresponding esters or acetals. The structural features common to all members of the group is a primary oxygenated functional group bonded directly to a benzene ring. The ring also contains hydroxy or alkoxy substituents.

The hydroxy- and alkoxy- substituted benzyl derivatives are raidly absorbed by the gastrointestinal tract, metabolised in the liver to yield benzoic acid derivatives and excreted primarily in the urine either unchanged or conjugated.

It is expected than aromatic esters and acetals will be hydrolysed in vivo through the catalytic activity of carboxylesterases, (A-esterases), Acetals hydrolyse uncatalysed in gastric juices and intestinal fluids to yield acetaldehydes. Substituted benzyl esters and benzaldehyde acetals are hydrolysed to the corresponding alcoholic alcohols and carboxylic acid.

In general hydroxy- and alkoxy- derivatives of benzaldehyde and benzyl alcohol are oxidised to the corresponding benzoic aid derivatives and, to a lesser extent reduced to corresponding benzyl alcohol derivatives. Following conjugation these are excreted in the urine. Benzyl alcohol derivatives may also be reduced in gut microflora to toluene derivatives. Flavor and Extract Manufacturers Association (FEMA)

The material may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.

The material may cause skin irritation after prolonged or repeated exposure and may produce on contact skin redness, swelling, the production of vesicles, scaling and thickening of the skin.

Starch Indicator, 0.5% (W/V) & STARCH, SOLUBLE & DISTILLED WATER

No significant acute toxicological data identified in literature search.

Starch Indicator, 0.5% (W/V) & SALICYLIC ACID

The salicylates are well absorbed by mouth, and oral bioavailability is assumed to be total. In humans, absorption through skin is more limited. The salicylates are expected to be broken down to salicylic acid, mostly in the liver, and then conjugated with glycine or glucuronide and excreted in the urine. The expected metabolism of the salicylates do not present toxicological concerns. Animal testing shows that acute toxicity by skin contact is very low, while acute toxicity by mouth is moderate. Salicylates do not possess genetic toxicity, and generally do not have the potential to cause cancer. The reproductive and developmental toxicity data on methyl salicylate shows that high doses which are toxic to the mother may cause toxicity to the embryo and birth defects. At concentrations likely to be encountered through their use as fragrance ingredients, salicylates are considered to be non-irritating to the skin.

Acute Toxicity	×	Carcinogenicity	X
Skin Irritation/Corrosion	×	Reproductivity	×
Serious Eye Damage/Irritation	×	STOT - Single Exposure	×
Respiratory or Skin sensitisation	×	STOT - Repeated Exposure	×
Mutagenicity	×	Aspiration Hazard	×

Legend:

🗶 – Data either not available or does not fill the criteria for classification

— Data available to make classification

SECTION 12 Ecological information

Toxicity

	Endpoint	Test Duration (hr)	Species	Value	Source
tarch Indicator, 0.5% (W/V)	Not Available	Not Available	Not Available	Not Available	Not Available
	Endpoint	Test Duration (hr)	Species	Value	Source
starch, soluble	Not Available	Not Available	Not Available	Not Available	Not Available
salicylic acid N	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50	72h	Algae or other aquatic plants	>100mg/l	2
	NOEC(ECx)	504h	Crustacea	<1mg/l	4
	LC50	96h	Fish	>100mg/l	2
	EC50	48h	Crustacea	118mg/l	2
	Endpoint	Test Duration (hr)	Species	Value	Source
Distilled Water Not Avail	Not Available	Not Available	Not Available	Not Available	Not Available
Legend:			CHA Registered Substances - Ecotoxicological Informa C Aquatic Hazard Assessment Data 6. NITE (Japan) - I		

Chemwatch: 10-35711 Page 8 of 10

Starch Indicator, 0.5% (W/V)

Starch mulcator, 0.5% (W/V)

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
salicylic acid	LOW	LOW
Distilled Water	LOW	LOW

Bioaccumulative potential

Ingredient	Bioaccumulation
salicylic acid	MEDIUM (BCF = 1000)

Mobility in soil

Version No: 2.1

Ingredient	Mobility	
salicylic acid	LOW (Log KOC = 23.96)	

SECTION 13 Disposal considerations

Waste treatment methods

Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.

A Hierarchy of Controls seems to be common - the user should investigate:

- Reduction
- Reuse
- Recycling
- Disposal (if all else fails)

Product / Packaging disposal

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. If it has been contaminated, it may be possible to reclaim the product by filtration, distillation or some other means. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

- ▶ DO NOT allow wash water from cleaning or process equipment to enter drains
- ▶ It may be necessary to collect all wash water for treatment before disposal.
- In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- Where in doubt contact the responsible authority.
- ▶ Recycle wherever possible
- Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitable treatment or disposal facility can be identified.
- Dispose of by: burial in a land-fill specifically licensed to accept chemical and / or pharmaceutical wastes or incineration in a licensed apparatus (after admixture with suitable combustible material).
- ▶ Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.

SECTION 14 Transport information

Labels Required

Marine Pollutant	NO	
HAZCHEM	HAZCHEM Not Applicable	

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

•			
Product name	Group		
starch, soluble	Not Available		
salicylic acid	Not Available		
Distilled Water	Not Available		

14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type		
starch, soluble	Not Available		
salicylic acid	Not Available		
Distilled Water	Not Available		

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

starch, soluble is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

Issue Date: 05/07/2024

Print Date: 14/11/2024

Version No: 2.1

Chemwatch: 10-35711

Starch Indicator, 0.5% (W/V)

Issue Date: 05/07/2024 Print Date: 14/11/2024

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 3

Australian Inventory of Industrial Chemicals (AIIC)

FEI Equine Prohibited Substances List - Controlled Medication

FEI Equine Prohibited Substances List (EPSL)

Distilled Water is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

Additional Regulatory Information

Not Applicable

National Inventory Status

autona inventory diatus				
National Inventory	Status			
Australia - AIIC / Australia Non- Industrial Use	Yes			
Canada - DSL	Yes			
Canada - NDSL	No (starch, soluble; salicylic acid; Distilled Water)			
China - IECSC	Yes			
Europe - EINEC / ELINCS / NLP	Yes			
Japan - ENCS	No (starch, soluble)			
Korea - KECI	Yes			
New Zealand - NZIoC	Yes			
Philippines - PICCS	Yes			
USA - TSCA	All chemical substances in this product have been designated as TSCA Inventory 'Active'			
Taiwan - TCSI	Yes			
Mexico - INSQ	No (starch, soluble)			
Vietnam - NCI	Yes			
Russia - FBEPH	No (starch, soluble)			
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.			

SECTION 16 Other information

Revision Date	05/07/2024
Initial Date	06/06/2024

SDS Version Summary

Version	Date of Update	Sections Updated
2.1	05/07/2024	Toxicological information - Acute Health (inhaled), Physical and chemical properties - Appearance, Hazards identification - Classification, Disposal considerations - Disposal, Exposure controls / personal protection - Engineering Control, Exposure controls / personal protection - Exposure Standard, Firefighting measures - Fire Fighter (fire fighting), First Aid measures - First Aid (eye), First Aid measures - First Aid (inhaled), First Aid measures - First Aid (skin), First Aid measures - First Aid (swallowed), Handling and storage - Handling Procedure, Composition / information on ingredients - Ingredients, Stability and reactivity - Instability Condition, Exposure controls / personal protection - Personal Protection (Respirator), Exposure controls / personal protection - Personal Protection (hands/feet), Accidental release measures - Spills (major), Accidental release measures - Spills (minor), Handling and storage - Storage (suitable container), Toxicological information - Toxicity and Irritation (Other), Identification of the substance / mixture and of the company / undertaking - Use, Name

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

- ▶ PC TWA: Permissible Concentration-Time Weighted Average
- ▶ PC STEL: Permissible Concentration-Short Term Exposure Limit
- IARC: International Agency for Research on Cancer
- ▶ ACGIH: American Conference of Governmental Industrial Hygienists
- ▶ STEL: Short Term Exposure Limit
- ► TEEL: Temporary Emergency Exposure Limit。
- ▶ IDLH: Immediately Dangerous to Life or Health Concentrations
- ► ES: Exposure Standard
- ▶ OSF: Odour Safety Factor
- NOAEL: No Observed Adverse Effect Level
- ▶ LOAEL: Lowest Observed Adverse Effect Level
- ▶ TLV: Threshold Limit Value
- ▶ LOD: Limit Of Detection
- OTV: Odour Threshold Value
- ▶ BCF: BioConcentration Factors
- ▶ BEI: Biological Exposure Index
- ▶ DNEL: Derived No-Effect Level

Chemwatch: 10-35711 Page 10 of 10 Issue Date: 05/07/2024 Version No: 2.1 Print Date: 14/11/2024

Starch Indicator, 0.5% (W/V)

- ▶ PNEC: Predicted no-effect concentration
- ► MARPOL: International Convention for the Prevention of Pollution from Ships
- ▶ IMSBC: International Maritime Solid Bulk Cargoes Code
- ▶ IGC: International Gas Carrier Code
- ▶ IBC: International Bulk Chemical Code
- ▶ AllC: Australian Inventory of Industrial Chemicals
- ▶ DSL: Domestic Substances List
- ▶ NDSL: Non-Domestic Substances List
- ▶ IECSC: Inventory of Existing Chemical Substance in China
- EINECS: European INventory of Existing Commercial chemical Substances
 ELINCS: European List of Notified Chemical Substances
 NLP: No-Longer Polymers

- ▶ ENCS: Existing and New Chemical Substances Inventory
- ▶ KECI: Korea Existing Chemicals Inventory
- ▶ NZIoC: New Zealand Inventory of Chemicals
- PICCS: Philippine Inventory of Chemicals and Chemical Substances
 TSCA: Toxic Substances Control Act
- ► TCSI: Taiwan Chemical Substance Inventory
- ▶ INSQ: Inventario Nacional de Sustancias Químicas
- ▶ NCI: National Chemical Inventory
- ▶ FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.